Results 81 to 90 of about 76,477,355 (241)
Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future
Journal of Experimental Pharmacology, 2020 Luca Navarini,1,* Damiano Currado,1,* Luisa Costa,2 Marco Tasso,2 Maria Sole Chimenti,3 Francesco Caso2 1Unit of Rheumatology, Immunology and Clinical Medicine, Università Campus Bio-Medico Di Roma, Rome, Italy; 2Rheumatology Unit, Department of ...
Navarini L +5 more
doaj
Long-term Safety and Comparative Efficacy of IL-17 Inhibitors in Treating Ankylosing Spondylitis [PDF]
Background: Ankylosing Spondylitis (AS) is a chronic inflammatory disease affecting the axial skeleton, characterized by spinal stiffness, sacroiliitis, and potential vertebral fusion.
Shaju, Ronald A +2 more
core +1 more source
Translophagy—A potential link between autophagy impairment and translational errors
FEBS Letters, EarlyView.Neurodegenerative diseases are characterised by the accumulation of abnormal proteins and protein aggregates, but their origin often remains unknown. We propose that selective autophagy removes damaged protein‐making machinery, preventing errors during protein synthesis.
Mykola V. Korolchuk +11 more
wiley +1 more source
Biologics for generalized pustular psoriasis: a systematic review and single-arm meta-analysis
Frontiers in ImmunologyIntroductionGeneralized pustular psoriasis (GPP) is a rare and potentially life-threatening auto-inflammatory disease. Currently, there are no consensus-based guidelines or universally accepted treatments.
Bai-lin Chen +6 more
doaj +1 more source
Научно-практическая ревматология, 2016 The paradigm of therapy for psoriatic arthritis (PsA) has recently undergone considerable changes due to development and clinical introduction of highly effective targeted drugs based on monoclonal antibodies – inhibitors of different cytokines. The data
T. V. Korotaeva
doaj +1 more source
Management of IL‐17 inhibitors‐induced paradoxical eczema in patients with plaque psoriasis
Dear Editor,Interleukin (IL)-17 inhibitors have significantly advancedthe treatment of moderate-to-severe psoriasis. However,paradoxical eczema is emerging as a treatment-relatedcutaneous adverse event, presenting both diagnostic andtherapeutic ...
Francesco Bellinato, Paolo Gisondi
core +1 more source
FEBS Letters, EarlyView.Mycobacterial 3‐methylcrotonyl‐CoA carboxylase uses a mobile biotin‐carrying domain to shuttle a carboxyl group between two catalytic sites, enabling carboxylation of 3‐methylcrotonyl‐CoA during leucine breakdown. Cryo‐electron microscopy captures the carrier at both sites and reveals an inward loop movement that may prevent futile rebinding to the ...
Ajit Yadav +2 more
wiley +1 more source
Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules
AntibodiesPsoriasis is a persistent, inflammatory condition affecting millions globally, marked by excessive keratinocyte proliferation, immune cell infiltration, and widespread inflammation.
Francesco Ferrara +9 more
doaj +1 more source
FEBS Letters, EarlyView.How do genomes gain new functional parts? In eukaryotes, which tend to evolve under weak selection, much of the genome is junk. Palazzo and Qiu borrow the logic of Markov chains to show how non‐functional DNA becomes functional through the appearance of intermediate states, which arise due to epistasis, buffering, and biochemical messiness, allowing ...
Alexander F. Palazzo, Yi Qiu
wiley +1 more source
Interleukin-17 Stimulates STAT3-Mediated Endothelial Cell Activation for Neutrophil Recruitment
Cellular Physiology and Biochemistry, 2015 Background/Aims: Interleukin-17 (IL-17) is a major pro-inflammatory cytokine that initiates and maintains inflammation. However, the molecular mechanisms as to how IL-17 influences endothelial cells to promote neutrophil recruitment are not fully ...
Shaopeng Yuan +5 more
doaj +1 more source